AI-designed drug reduces fentanyl consumption in animal models by targeting serotonin receptors
A recent study published in the Proceedings of the National Academy of Sciences suggests that a novel drug developed using artificial intelligence can significantly reduce fentanyl consumption in animal models. The experimental medication targets specific serotonin receptors in the brain to restore neural pathways altered by addiction. These findings provide evidence that this new compound could eventually offer a non-addictive treatment option for people experiencing opioid use disorder. Opioid use disorder currently affects millions of people, with synthetic opioids like fentanyl driving a severe public health crisis. Seeking alternative treatments, scientists focused on creating a therapy that addresses the neurological changes caused by addiction without relying on opioid-based medications. “New therapeutics for opioid use disorder are desperately needed,” said study author Christie D. Fowler, a chancellor’s fellow and professor in the Department of Neurobiology and Behavior at the University of California, Irvine. “Just about everyone has been impacted by the opioid epidemic. These are people’s mothers, fathers, sisters, brothers, sons, and daughters.” Fowler, who also serves as the co-director of the UC Irvine Center for …


